-$0.52 Earnings Per Share Expected for Aptinyx Inc (NASDAQ:APTX) This Quarter

Brokerages expect Aptinyx Inc (NASDAQ:APTX) to announce earnings per share of ($0.52) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Aptinyx’s earnings. The highest EPS estimate is ($0.49) and the lowest is ($0.57). Aptinyx reported earnings of ($1.83) per share in the same quarter last year, which would suggest a positive year over year growth rate of 71.6%. The firm is scheduled to report its next quarterly earnings results before the market opens on Monday, August 12th.

On average, analysts expect that Aptinyx will report full year earnings of ($2.15) per share for the current year, with EPS estimates ranging from ($2.25) to ($2.09). For the next financial year, analysts anticipate that the business will post earnings of ($2.06) per share, with EPS estimates ranging from ($2.31) to ($1.79). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that cover Aptinyx.

Aptinyx (NASDAQ:APTX) last announced its earnings results on Tuesday, May 14th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.04). Aptinyx had a negative net margin of 1,166.40% and a negative return on equity of 37.53%. The business had revenue of $0.89 million for the quarter, compared to the consensus estimate of $1.00 million.

Several equities analysts have recently issued reports on APTX shares. Svb Leerink started coverage on Aptinyx in a research report on Thursday, June 20th. They issued an “outperform” rating and a $12.00 price target for the company. ValuEngine raised Aptinyx from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Cowen reaffirmed a “buy” rating on shares of Aptinyx in a research report on Monday, June 10th. Zacks Investment Research raised Aptinyx from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research report on Tuesday, July 16th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Aptinyx in a research report on Tuesday, April 30th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $12.71.

A number of large investors have recently modified their holdings of the business. Great West Life Assurance Co. Can purchased a new position in Aptinyx in the 4th quarter worth about $40,000. Barclays PLC raised its position in Aptinyx by 87.1% in the 4th quarter. Barclays PLC now owns 9,323 shares of the company’s stock worth $154,000 after buying an additional 4,340 shares during the last quarter. Gabelli Funds LLC raised its position in Aptinyx by 45.9% in the 2nd quarter. Gabelli Funds LLC now owns 15,901 shares of the company’s stock worth $53,000 after buying an additional 5,000 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its position in Aptinyx by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock worth $120,000 after buying an additional 5,652 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Aptinyx by 30.6% in the 4th quarter. Bank of New York Mellon Corp now owns 43,887 shares of the company’s stock worth $726,000 after buying an additional 10,284 shares during the last quarter. 58.40% of the stock is owned by institutional investors and hedge funds.

Shares of APTX traded down $0.01 during trading hours on Monday, hitting $3.53. The company had a trading volume of 73,193 shares, compared to its average volume of 159,085. The company’s fifty day moving average is $3.62. The stock has a market capitalization of $118.47 million, a PE ratio of -1.34 and a beta of -0.03. Aptinyx has a 52-week low of $2.88 and a 52-week high of $32.25.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Recommended Story: Street Name

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.